Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01789320 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
A Phase 1 study, sponsored by Clearside Biomedical.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01789320 is a Phase 1 study that has completed, run by Clearside Biomedical. The registered enrollment target is 11 participants.
The verdict
NCT01789320, a Phase 1 study, has completed, sponsored by Clearside Biomedical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study is designed to determine the safety and tolerability of a single microinjection of triamcinolone acetonide (TRIESENCE®) into the suprachoroidal space (SCS) of patients who have non-infectious uveitis.
Interventions
- DRUG triamcinolone acetonide (Triesence®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-02 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01789320
The ClinicalTrials.gov registry entry for NCT01789320 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clearside Biomedical, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which triamcinolone acetonide (Triesence®) is the first listed.
NCT01789320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01789320 about?
NCT01789320 is a clinical study titled "Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis". This study is designed to determine the safety and tolerability of a single microinjection of triamcinolone acetonide (TRIESENCE®) into the suprachoroidal space (SCS) of patients who have non-infectious uveitis.
What is the current status of trial NCT01789320?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2013-02. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01789320?
The interventions under investigation include: triamcinolone acetonide (Triesence®) (DRUG).
Who is sponsoring clinical trial NCT01789320?
This trial is sponsored by Clearside Biomedical, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.